Rimantadine

Subscribe to Selected New Research on Rimantadine

284 relevant articles (43 outcomes, 28 trials/studies) found for this Drug

Description: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.

Also Known As:

Flumadine; Forest Brand of Rimantadine Hydrochloride; Riamantadine; Rimantadine Hydrochloride; Roche Brand of Rimantadine Hydrochloride; Roflual; Hydrochloride, Rimantadine; Remantadine; Tricyclo(3.3.1.13,7)decane-1-methanamine, alpha-methyl-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Cyclic Hydrocarbons: 2

Alicyclic Hydrocarbons: 1

Experts

1.	Demicheli, V: 5 articles (01/2006 - 01/2000)
2.	Rivetti, D: 5 articles (01/2006 - 01/2000)
3.	Deeks, J J: 4 articles (01/2004 - 01/2000)
4.	Jefferson, T O: 3 articles (01/2002 - 01/2000)
5.	Jefferson, T: 2 articles (01/2006 - 01/2004)
6.	Alves da Cunha, Ajl: 1 article (01/2008)
7.	Alves Galvão, Mg: 1 article (01/2008)
8.	Alves da Cunha, A J L: 1 article (01/2008)
9.	Rocha Crispino Santos, M A: 1 article (01/2008)
10.	Rocha Crispino Santos, Ma: 1 article (01/2008)

Related Diseases

1.	Human Influenza (Influenza) 09/01/1990 - "These findings indicate that low-dose rimantadine is well tolerated and highly effective for the prevention of influenza A illness in healthy adults." 10/14/1988 - "A gas chromatographic-mass spectrometric procedure has been developed for the quantitation in plasma and urine of the enantiomers of rimantadine, an antiviral drug effective against type A influenza" 10/01/1987 - "A GC-MS procedure has been developed for the quantitation in plasma and urine of rimantadine, an antiviral drug effective against type A influenza" 05/01/1978 - "The therapeutic and prophylactic efficacy of rimantadine in familial foci during influenza A1 outbreaks was studied" 05/01/1969 - "The therapeutic efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak." Get all the results and reference details, order at left...
2.	Infection 12/01/2004 - "Maximum synergy against A/New Caledonia/20/99 (H1N1) virus infection was observed with <2.5 microM rimantadine paired with low concentrations of NA inhibitors" 10/01/2003 - "Thus, rimantadine should be the preferred agent in this class for the prevention of influenza A virus infection and should be made available in Canada." 10/01/2003 - "A case for rimantadine to be marketed in Canada for prophylaxis of influenza A virus infection." 07/01/1999 - "CONCLUSIONS AND CLINICAL RELEVANCE: Oral administration of rimantadine to horses can safely ameliorate clinical signs of influenza virus infection." 05/01/1999 - "Sensitivity to rimantadine is higher in a variant obtained similarly by cell culture infection with rimantadine-resistant FPV" Get all the results and reference details, order at left...
3.	Pneumonia (Pneumonitis) 09/01/1987 - "In the groups of mice infected with remantadine-resistant strain of influenza virus and Staphylococcus remantadine showed no significant effect on these parameters: the lethality decreased by 6.7% only, the average survival time increased only by 0.33 days, the incidence of pneumonia decreased by 9%, its intensity by 19.2%; influenza virus titres in the lung tissue did not change significantly." 09/01/1987 - "When the drug was injected to the mice infected with remantadine-sensitive strain of influenza A virus and Staphylococcus the lethality decreased from 93.3% to 26.7%, the survival time increased from 3.8 to 10.1 days, the incidence of pneumonia decreased from 85.7% to 48.7%, the average intensity of pneumonia decreased from 66.4% to 9.9%, and virus titres in the lungs decreased by 3.5-4.0 lg EID50 (p less than 0.05)" 01/01/1980 - "Prevention of pneumonia in influenza A by means of a new anti-influenza drug rimantadine]" 11/01/2004 - "Six untreated patients (18%) developed pneumonia, whereas 1 (13%) of 8 patients treated with rimantadine and 0 of 9 treated with oseltamivir developed pneumonia" 06/01/2001 - "Antiviral treatment was begun 4 +/- 3 days from initiation of symptoms in patients with pneumonia and consisted of oseltamivir (35.2%), rimantadine (5.8%), or a combination of both (17.6%)" Get all the results and reference details, order at left...
4.	Fever (Fevers) 08/01/1987 - "Children receiving rimantadine showed significantly greater reduction in fever and improvement in daily scores for symptoms and severity of illness during the first three days" 09/01/1991 - "In a family-based study, rimantadine treatment for 10 days (24 children and adults) was associated with significant decreases in the number of days to a 50% reduction in symptoms (mean difference, 2.5 days), days of fever (1.6 days), and days of restricted activity (1.5 days) compared with the results obtained with placebo-treated patients (32 children and adults)" 01/06/2000 - "73-1.29), and oral rimantadine significantly shortened duration of fever (by 1.27 days - 95%CI: 0.77-1.77)" 01/01/1994 - "Remantadine application decreased fever and complication rates and reduced the duration of intoxication symptoms and the diseases as a whole" 03/20/1981 - "By 48 hours after initiation of therapy, amantadine and rimantadine recipients had significantly less fever and greater improvement compared with subjects given the placebo" Get all the results and reference details, order at left...
5.	Influenza in Birds (Avian Flu) 09/01/2005 - "The fear that avian influenza could be a precursor to the next pandemic is real and inevitable, given the extremely high case-fatality ratio among confirmed cases and that genetic sequencing of influenza A (H5N1) viruses from human cases in Thailand and Vietnam show resistance to the antiviral medication amantadine and rimantadine" 03/01/1985 - "Virion deproteinization and viral RNA transport to the isolated cell nuclei have been studied in the presence of rimantadine with rimantadine-sensitive influenza viruses fowl plague (H7N7), A/Krasnodar/101/59 (H2N2) and rimantadine-resistant influenza strains (WSN/H1N1 and A/Krasnodar/101/59-R)" 03/01/2006 - "Commercial drugs, such as rimantadine, amantadine, rivabirine, and arbidole, are effective in suppressing the in vitro reproduction of highly pathogenic avian influenza A/H5N1 viruses" 07/01/2005 - "The antiviral agents rimantadine, ribavirine, and tamiflu were tested for the effects on the reproduction of avian influenza virus A/H5 in in vitro experiments" Get all the results and reference details, order at left...
51 Diseases and 284 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Amantadine (Aman)
2.	Antiviral Agents (Antivirals)
3.	Zanamivir (Relenza)
4.	Oseltamivir (Tamiflu)
5.	Neuraminidase (Sialidase)
6.	Ribavirin (Virazole)
7.	Ion Channels (Ion Channel)
8.	arbidol
9.	Influenza Vaccines (FluMist)
10.	Interferons
85 Drugs and Important Bio-Agents and 208 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Chemoprevention
2.	Drug Therapy (Chemotherapy)
3.	Long-Term Care
4.	Home Nursing (Nursing, Home)
5.	Transplants (Transplant)
10 Therapies and Procedures and 18 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>